“I think we are the best positioned company to stay with the remedies (conditions) imposed by Brussels for the merger of Orange with MásMóvil”, Óscar Vilda, brand new CEO of the teleco, presented himself this Wednesday with confidence.

The so-called remedies are the assets that the European Union competition authorities are expected to force Orange and MásMóvil to divest in order to authorize their merger. Vilda has argued that at this time, “Finetwork is the only company with national implementation, integrated customer systems and we would not be penalized by the obligation to release assets since the contract with Vodafone, (on whose lines it is active at this time), ends in April 2024”, he assured.

In the opinion of the new director of Finetwork, Digi, the company of Romanian origin on which, until now, more eyes have been fixed as the recipient of these remedies “should not be chosen since it has already begun its own process of deploying its own networks” .

In any case, we will have to wait until July, in the best of cases, to find out if Brussels will finally impose demands for the Spanish merger and it will not be until after the summer when the final decision is known.

Meanwhile, Finetwork assures that it has already received interest from three investment funds, one of them international and without a presence in Spain, to finance the purchase of these assets. “Although depending on the decision in Europe between our organic growth and financing from a financial institution with which we are already speaking, we may not need to enter capital and grow only with debt,” says Vilda.

The objective of this new strategic plan sets the goal of reaching 15 million homes in 2024 and 20 two years later. It currently has 900,000 customers and hopes to surpass one million next fall.

Regarding its commercial policy, Finetwork wants to go beyond a low cost bet and will continue to focus its strategy on boosting its brand image through sponsorships and events. “We are not here to break the market”, Vilda has confirmed.